Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marius C Kuschma"'
Autor:
Laween Uthman, Antonius Baartscheer, Cees A. Schumacher, Jan W. T. Fiolet, Marius C. Kuschma, Markus W. Hollmann, Ruben Coronel, Nina C. Weber, Coert J. Zuurbier
Publikováno v:
Frontiers in Physiology, Vol 9 (2018)
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are the first antidiabetic compounds that effectively reduce heart failure hospitalization and cardiovascular death in type 2 diabetics. Being explicitly designed to inhibit SGLT2 in the kidney, SGLT
Externí odkaz:
https://doaj.org/article/4f40533026864e7b8f7d08956deefdb3
Autor:
Markus W. Hollmann, Benedikt Preckel, Jens Kessler, Gregor Römer, Nina C. Weber, Marleen Boomsma, Coert J. Zuurbier, Laween Uthman, Jeroen Hermanides, Marius C Kuschma
Publikováno v:
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, 35(6). Kluwer Academic Publishers
Cardiovascular Drugs and Therapy
Cardiovascular Drugs and Therapy
Purpose Vascular inflammation and disturbed metabolism are observed in heart failure and type 2 diabetes mellitus. Glycolytic enzyme hexokinase II (HKII) is upregulated by inflammation. We hypothesized that SGLT2 inhibitors Canagliflozin (Cana), Empa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b77ac0c00fae9fd5d5b748a0ff50a42d
https://pure.amc.nl/en/publications/novel-antiinflammatory-effects-of-canagliflozin-involving-hexokinase-ii-in-lipopolysaccharidestimulated-human-coronary-artery-endothelial-cells(d133d916-3629-4d1b-bcb7-1d87e2219b28).html
https://pure.amc.nl/en/publications/novel-antiinflammatory-effects-of-canagliflozin-involving-hexokinase-ii-in-lipopolysaccharidestimulated-human-coronary-artery-endothelial-cells(d133d916-3629-4d1b-bcb7-1d87e2219b28).html
Autor:
Ruben Coronel, Marius C Kuschma, Laween Uthman, Cees A. Schumacher, Nina C. Weber, Antonius Baartscheer, Markus W. Hollmann, Jan W.T. Fiolet, Coert J. Zuurbier
Publikováno v:
Frontiers in Physiology, Vol 9 (2018)
Frontiers in Physiology
Frontiers in Physiology
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are the first antidiabetic compounds that effectively reduce heart failure hospitalization and cardiovascular death in type 2 diabetics. Being explicitly designed to inhibit SGLT2 in the kidney, SGLT